Circulating concentrations of vitamin D in relation to pancreatic cancer risk in European populations.
Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31146. [Epub ahead of print]
| Vitamin D level (nmol) | Risk of not getting PC |
| <25 | 0.71 |
| 25 – 50 | 0.94 |
| 50 – 75 | 1.00 |
| 75 – 100 | 1.12 |
| 100 | 1.26 |
Europeans with > 40 ng (vs <10 ng) were 55 % less likely to get PC (.29+.26)
With 738 cases there was not enough data to be statistically significant
Note: While many groups are now defining Optimal as > 40 ng,
higher levels typically show more benefit
- Dr. who got patients to vitamin D level of 80 ng resulted in 75% fewer visits to doctor's office
He is mentioned in the 5 minute video Does Less Sun mean More Disease
See also VitaminDWiki
- Omega-3 should help Pancreatic Cancer in 5 ways – June 2017
- Pancreatic Cancer Survival 40 percent more likely if had adequate vitamin D (30 ng) – June 2016
- Pancreatic cancer 30 percent less likely in Australians who got lots of UVB (vitamin D) – Dec 2013
- Restoring vitamin D levels to Pancreatic patients required up to 20000 IU daily – May 2012
van Duijnhoven FJB1,2, Jenab M3, Hveem K4, Siersema PD5, Fedirko V6, Duell EJ7, Kampman E2, Halfweeg A2, van Kranen HJ1, van den Ouweland JMW8, Weiderpass E9,10,11,12, Murphy N3, Langhammer A4, Ness-Jensen E4, Olsen A13, Tjønneland A13, Overvad K14, Cadeau C15,16, Kvaskoff M15,16, Boutron-Ruault MC15,16, Katzke VA17, Kühn T17, Boeing H18, Trichopoulou A19,20, Kotanidou A19,21, Kritikou M19, Palli D22, Agnoli C23, Tumino R24, Panico S25, Matullo G26,27, Peeters P28,29, Brustad M9, Standahl Olsen K9, Lasheras C30, Obón-Santacana M6, Sánchez MJ31,32, Dorronsoro M33, Chirlaque MD32,34,35, Barricarte A32,36,37, Manjer J38, Almquist M39, Renström F40,41, Ye W11,42, Wareham N43, Khaw KT44, Bradbury KE45, Freisling H3, Aune D29, Norat T29, Riboli E29, Bueno-de-Mesquita HB1,5,29,46.
Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D against pancreatic cancer. However, this has not been confirmed by analytical epidemiological studies. We aimed to examine the association between pre-diagnostic circulating vitamin D concentrations and pancreatic cancer incidence in European populations. We conducted a pooled nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health Study's second survey (HUNT2) cohorts. In total, 738 primary incident pancreatic cancer cases (EPIC n=626; HUNT2 n=112; median follow-up = 6.9 years) were matched to 738 controls. Vitamin D [25(OH)D2 and 25(OH)D3 combined] concentrations were determined using isotope-dilution liquid chromatography-tandem mass spectrometry. Conditional logistic regression models with adjustments for body mass index and smoking habits were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95%CI).
Compared with a reference category of >50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42-1.20); 0.94 (0.72-1.22); 1.12 (0.82-1.53); and 1.26 (0.79-2.01) for clinically pre-defined categories of ≤25; >25 to 50; >75 to 100; and >100 nmol/L vitamin D, respectively (p for trend = 0.09). Corresponding analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations with pancreatic cancer risk (p for trend = 0.23). Although these findings among participants from the largest combination of European cohort studies to date show increasing effect estimates of pancreatic cancer risk with increasing pre-diagnostic concentrations of vitamin D, they are not statistically significant. This article is protected by copyright. All rights reserved.
PMID: 29114875 DOI: 10.1002/ijc.31146